The most common grade @ or worse adverse events in both treatment groups were haematotoxicity ( @ -LSB- @ % -RSB- of @ patients in the cetuximab group vs @ -LSB- @ % -RSB- of @ patients in the bevacizumab group ) , skin reactions ( @ -LSB- @ % -RSB- vs six -LSB- @ % -RSB- ) , and diarrhoea ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .